JUL 08, 2019 7:06 PM PDT

A CRISPR System can Edit Only a Defective Copy of a Gene

WRITTEN BY: Carmen Leitch

Researchers have modified and refined the gene-editing tool CRISPR/Cas9 since it was developed. Now researchers have used a more precise version of the editor to repair a genetic mutation in a mouse model of hearing loss. The scientists applied a variation of the Cas9 enzyme that can identify the disease-causing gene mutation more specifically; it can alter a single, erroneous copy of the gene and leave the correct one alone. The approach was able to target a single error in the three billion bases of the mouse genome and fix it. The work has been reported in Nature Medicine.

Image credit: Max Pixel

"Our results demonstrate that this more refined, better targeted version of the now-classic CRISPR/Cas9 editing tool achieves an unprecedented level of identification and accuracy," said study co-senior investigator David Corey, the Bertarelli Professor of Translational Medical Science in the Blavatnik Institute at Harvard Medical School.

We carry two copies of each chromosome, and so we have two copies of every gene (except sex chromosomes). Some genetic mutations cause disease only when a person carries two defective copies of a gene, while others can result in illness with only one mutated copy. In the case of the Tmc1 gene, progressive hearing loss, like what happened to Beethoven occurs because of a single mutant copy of Tmc1; the mice that model the mutation are referred to as Beethoven mice. They carry a single copy of the defective Tmc1 gene, and one correct copy. Though it's still a long way off from being applied to humans, this work shows that it is possible to edit single copies of mutated genes while leaving the correct copy unaltered.

"We believe our work opens the door toward a hyper-targeted way to treat an array of genetic disorders that arise from one defective copy of a gene," said study co-senior investigator Jeffrey Holt, Harvard Medical School professor of otolaryngology and neurology at Boston Children's Hospital. "This truly is precision medicine."

The CRISPR/Cas9 system, which is derived from bacteria, relies on an RNA molecule (gRNA) to guide the genome-cutting Cas9 enzyme to the right spot. This gRNA is about twenty nucleotides long. While it can be specific, there is some tolerance for mismatches and some gRNAs can end up targeting the wrong places in the genome. A modified version of Cas9 was generated using the Staphylococcus aureus bacterium rather than Streptococcus pyogenes, where standard Cas9 comes from. This modified enzyme identifies the mutation - a single change from an A to a T, and edits only the mutated copy of Tmc1.

"We took advantage of the fact that this system recognizes mutant DNA but not normal DNA and uses a dual recognition system for enhanced precision," said the first author of the study Bence Gyorgy. "This approach resulted in an unprecedented level of specificity in targeting the mutant gene."

After testing this strategy in mice with and without the mutation, they found that gene edits only happened in mice with the mutation. Two months after the treatment, a hearing test showed that the Beethoven mice had much better hearing that untreated mice. Some treated mice could hear sounds at 25 to 30 decibels, making their hearing about as good as normal mice. A structural analysis of hearing cells showed that they looked healthy in the treated mice.

The disorder is characterized by progressive loss of hearing, so the impact of the therapy was tested over time. Untreated mice could not hear by six months of age while the treated mice could still hear low and high frequencies - the latter are normally lost in Beethoven mice by month one. Animals that got the treatment but lacked the mutation remained unchanged, showing that the treatment was safe.

This strategy was also found to be effective in human cells carrying the mutation. While it needs more testing before it's applied to people, it has the potential to repair 3,759 other defective gene variants.

"To be sure, this is the first step in a long journey," Holt said. "But what we have here is proof of principle that demonstrates this highly specific, highly targeted treatment could be developed to selectively silence genes that carry single-point mutations and potentially treat many other forms of human disease."

Learn more about the improved specificity of CRISPR/Cas9 from the video.


Sources: AAAS/Eurekalert! Via Harvard Medical School, Nature Medicine

About the Author
BS
Experienced research scientist and technical expert with authorships on over 30 peer-reviewed publications, traveler to over 70 countries, published photographer and internationally-exhibited painter, volunteer trained in disaster-response, CPR and DV counseling.
You May Also Like
AUG 29, 2022
Health & Medicine
US-Funded Research to be Open Access by 2026 Under New Federal Guidance
AUG 29, 2022
US-Funded Research to be Open Access by 2026 Under New Federal Guidance
If you have ever done research for school or work, or simply been curious about a scientific finding and wanted to read ...
SEP 15, 2022
Clinical & Molecular DX
Critical Success Factors for Automating Laboratory Workflows
SEP 15, 2022
Critical Success Factors for Automating Laboratory Workflows
Staff shortages and increasing sample volume are the factors typically driving laboratories to assess their current work ...
OCT 02, 2022
Immunology
A Network Linking Aging, Inflammation, and Diet
OCT 02, 2022
A Network Linking Aging, Inflammation, and Diet
Our immune system is crucial to our health. It has to respond to pathogens and tissue damage quickly by initiating infla ...
OCT 21, 2022
Coronavirus
Recognizing the Importance of SARS-CoV-2 'Accessory' Genes
OCT 21, 2022
Recognizing the Importance of SARS-CoV-2 'Accessory' Genes
The genome of the virus that causes COVID-19, SARS-CoV-2, is very small. But it encodes for more than just the spike pro ...
OCT 12, 2022
Plants & Animals
New gibbon fossils suggest the genus is 8 million years old
OCT 12, 2022
New gibbon fossils suggest the genus is 8 million years old
New fossil teeth and face suggest gibbon ancestors are older than thought
NOV 05, 2022
Health & Medicine
Autism Study Reveals Widespread Transcriptomic Changes in the Brain
NOV 05, 2022
Autism Study Reveals Widespread Transcriptomic Changes in the Brain
We know of some risk factors for autism spectrum disorder, and like other neuropsychiatric disorders, there is a genetic ...
Loading Comments...